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a b s t r a c t
Here we report two new RUNX1 mutations in one patient with congenital thrombocytopenia that
transformed into a high grade myelodysplastic syndrome with myelomonocytic features. The ﬁrst
mutation was a nucleotide base substitution from guanine to adenine within exon 8, resulting in a
nonsense mutation in the DNA-binding inhibitory domain of the Runx1 protein. This nonsense mutation
is suspected a de novo germline mutation since both parents are negative for the mutation. The second
mutation identiﬁed was an in-frame six nucleotide base pair insertion in exon 5 of the RUNX1 gene,
which is predicted to result in an insertion in the DNA-binding runt homology domain (RHD). This
mutation is believed to be a somatic mutation as it was mosaic before allogeneic hematopoietic cell
transplantation and disappeared after transplant. As no other genetic mutation was found using genetic
screening, it is speculated that the combined effect of these two RUNX1 mutations may have exerted a
stronger dominant negative effect than either RUNX1 mutation alone, thus leading to a myeloid
malignancy.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Runx1 is an important transcription factor for myeloid devel-
opment [1,2]. Impairments in Runx1 function lead to a block in
myeloid differentiation and can drive leukemogenesis [3]. Clini-
cally, germline mutations in the RUNX1 gene cause an autosomal
dominant familial platelet disorder (FPD) with propensity to
transform into myeloid malignancies such as myelodysplastic
syndromes (MDS), chronic myelomonocytic leukemia (CMML),
and acute myeloid leukemia (AML) [4–8]. Although rare, enhanced
awareness of RUNX1 mutations has led to increased reports in
recent literature, suggesting that the disease is actually more
common than once thought.[9] Germline mutations in RUNX1
have important clinical implications and knowledge about such
mutations is critical.
2. Case report
We report a case of an 18 year-old Caucasian male whowas found
to have thrombocytopenia at birth, with a platelet count of 58,000/
mm3. Bone marrow biopsy was ﬁrst performed in 1993, at 13
months of age, and showed 70–80% cellular marrow with occasional
megakaryocytes and no evidence of dysplastic changes or increased
monocytes. There was no history of thrombocytopenia or bleeding
tendency in his family. Throughout childhood, his platelet counts
averaged between 90,000 and 120,000/mm3. He had a lifelong
history of easy bruising, however had no major bleeding episodes.
He underwent several operations including spinal fusion surgery for
scoliosis, later requiring revision, and a tonsillectomy with adenoi-
dectomy. He received pre- and post-operative platelet transfusions as
well as intravenous aminocaproic acid for his spinal operations
without signiﬁcant bleeding. He also had history of several infections,
including lower extremity cellulitis, periorbital cellulitis, and a
perirectal abscess. The patient was otherwise developmentally and
phenotypically normal and was of normal intelligence.
In 2007, the patient was noted to have a mild normocytic anemia
with hemoglobin and hematocrit of 10 g/dL and 30%. Four years later,
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at 18 years of age, the patient developed a mild leukopenia (3200/
mm3), as well as worsening of his baseline thrombocytopenia to
around 60,000/mm3. Bone marrow biopsy revealed 65–70% cellular
marrow with 10% myeloblasts aberrantly expressing CD7, dysplastic
erythroid progenitors and megakaryocytes, increased monocytes
(25%), increased eosinophils, and no ﬁbrosis. Cytogenetic analysis
revealed normal male karyotype. FISH was negative for AML1-ETO
(RUNX1-RUNX1T1) gene fusion and CBFB gene rearrangements.
Molecular studies for CEBPA, c-MPL, FLT3, and NPM1 gene mutations
were negative. The bone marrow pathology was interpreted as a
high grade MDS (RAEB-1, Intermediate-2 IPSS risk). Although there
were some features of CMML in the bone marrow, the patient did not
have an elevated number of peripheral blood monocytes to meet
criteria for this diagnosis.
The patient's pancytopenia worsened over the ensuing weeks
and follow-up bone marrow biopsy revealed a marrow that was
75% cellular with 15% dysplastic myeloblasts aberrantly expressing
CD7, 23% dysplastic monocytes, and 5% eosinophils. Cytogenetics
showed normal male karyotype. FISH was negative for abnormal-
ities in chromosomes 5, 7, 8 and 20. Additionally, FISH probes for
PDGFRA, PDGFRB, CBFB, and FGFR1 detected no gene rearrange-
ments. Genetic analysis found no mutations in FLT3 or NPM1.
Lumbar puncture showed no evidence of central nervous system
(CNS) involvement.
Because of his history of thrombocytopenia since birth evolving to
MDS, DNA sequencing of RUNX1 was performed on both blood and
buccal swab specimens. Two mutations were discovered: the ﬁrst
mutation, c.837G4A, was a nucleotide base substitution from guanine
to adenine within exon 8 (Fig. 1), which is predicted to result in a
nonsense mutation of amino acid tryptophan (W) to a premature stop
codon (X) (p.W279X) in the DNA-binding inhibitory domain of the
Runx1 protein. This mutation was found in 100% of cells analyzed. The
second mutation identiﬁed, c.422_423insAAGGCC, was an in-frame six
nucleotide base pair insertion in exon 5 of the RUNX1 gene, which is
predicted to result in an insertion of an arginine (R) and proline (P)
(p.S141_A142insRP) in the DNA-binding runt homology domain (RHD)
of the Runx1 protein. This second mutation displayed a mosaic pattern.
Peripheral blood from both the mother and father showed wild
type RUNX1 only and no evidence of mutations.
The patient was diagnosed with a RUNX1 double mutant, pre-
leukemic MDS with myelomonocytic differentiation and adminis-
tered induction chemotherapy with cytarabine and idarubicin.
Prior to receiving induction chemotherapy, the patient elected
for sperm banking to prepare for possible assisted reproductive
technology in the future. The patient achieved an immediate
complete remission (CR) following induction chemotherapy and
then received once cycle of consolidation treatment with high
dose cytarabine. Because of his underlying RUNX1 mutations and
high risk for relapse disease [10], he immediately underwent an
allogeneic hematopoietic cell transplant (allo-HCT) from a
matched unrelated donor. Six months after transplant, oral
mucosa cells harvested by buccal swab were analyzed for RUNX1
sequencing and revealed persistence of the exon 8 RUNX1 muta-
tion with disappearance of the exon 5 insertion mutation. These
results support the notion of a constitutional RUNX1 mutation in
exon 8 and an accessory somatic RUNX1 mutation in exon 5.
Two years after allo-HCT the patient has normal blood counts,
normal bone marrow morphology, no evidence of graft-versus-
host disease, and is off immunosuppression.
3. Discussion
A familial platelet disorder with a propensity to myeloid
malignancy (FPD/MM) was ﬁrst reported in 1978 and since then
approximately 30 pedigrees with RUNX1 germline mutations have
been reported in the literature [9,11]. The RUNX1 gene is com-
posed of 10 exons (1–6, 7A, 7B, 7C and 8). Distinct promoter
Fig. 1. Germline RUNX1 gene mutation in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Arrows indicate RUNX1
c.837G4A (p.W279X) mutation using Sanger sequencing.
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regions and variable splicing leads to transcription of different
isoforms, the longest being 480 amino acids in length. The N-
terminal region encodes for the runt homology domain (RHD),
which mediates both DNA binding and heterodimerization with its
partner, core binding factor (CBF) beta. This region is coded on
exons 3 through 5, which correlates to amino acids 50–177, and
includes three speciﬁc DNA binding sites. The C-terminal region
regulates gene transcription and encodes for the transcription
activation domain on exons 7B and 8 (amino acids 243–371).
Within this domain, there is a speciﬁc region known as the DNA-
binding inhibitory domain (amino acids 184–291), which is
important in down-regulating gene expression and a key site for
gene mutations.
The Runx1 protein acts by binding with CBF-beta to form a
transcription factor complex that is expressed in hematopoietic
stem cells and regulates expression of several important
hematopoietic genes. Runx1 also plays a role in the transcription
of many genes involved in normal platelet function, which
explains the mild thrombocytopenia and platelet dysfunction seen
in FPD/MM [12,13]. Runx1 is also important in regulating tran-
scription of many tumor suppressor genes [14,15], and has been
found to regulate DNA damage repair [16].
Aberrations of the RUNX1 gene are commonly seen in sporadic
forms of AML and MDS, with chromosomal translocations more
common in AML and point mutations in MDS [17–20]. In FPD/MM,
RUNX1 mutations are very heterogeneous and are often speciﬁc to
individual pedigrees. The most common mutation site involves the
RHD domain located near the N-terminus of Runx1, within exons
three to ﬁve of RUNX1 [9]. The RHD domain is especially prone to
mutations as it contains easily mutable primary sequences that are
prone to transition-type mutations via methylation of a cytidine
residue [17]. Some mutations are more damaging than others and
confer a greater risk of transformation to malignancy. Mutations
that cause haploinsufﬁciency are most common; however, muta-
tions that act in a “dominant negative” fashion are particularly
high risk and act by competing for DNA binding sites or by
preferentially binding to CBF-beta, thereby reducing wildtype
Runx1 activity below 50%. As compared to mutations that cause
haploinsufﬁciency, dominant negative mutations have a higher
incidence of progression to MDS/AML [7,21]. Likewise, Runx1
mutations at the C-terminus have enhanced capacity to bind
DNA due to loss of the DNA-binding inhibitory domain, leading
to preferential expression of the mutant allele.
When mutated, Runx1 enhances myeloid cell proliferation,
blocks cell differentiation, and leads to genomic instability, result-
ing in leukemogenesis [22–24]. Although RUNX1 mutations are
very important in promoting leukemic transformation, they are
insufﬁcient to initiate disease by themselves. Secondary mutations
are required before patients develop malignancy [25]. An impor-
tant second hit is that of the otherwise normal wildtype RUNX1
gene, resulting in biallelic mutations in RUNX1 [26]. This has led
some to refer to RUNX1 as the “gatekeeper gene” in the pathogen-
esis of RUNX1-associated acute leukemias [27].
The case presented above is an example of a spontaneous
RUNX1 germline mutation associated with a congenital thrombo-
cytopenia that evolved into a myelomonocytic malignancy likely
due to a secondary RUNX1 somatic mutation. Reported here for the
ﬁrst time is a c.837G4A nonsense mutation in exon 8 resulting
premature stop codon within the DNA-binding inhibitory domain,
an important self-regulator of RUNX1 transcription. Truncated
Runx1 proteins are a common phenotype resulting in malignant
transformation, and mutations in the DNA-binding inhibitory
region are known to have a dominant negative effect [20]. Also
reported here is a novel second mutation that is an in-frame
insertion of six nucleotides within exon 5 of the RUNX1 gene. This
second mutation involved the DNA-binding RHD, where mutations
resulting in CMML have been reported before [28]. The second
mutation is believed to be a secondary somatic mutation because
it was mosaic prior to transplant and disappeared after transplant.
Also, because of the absence of other genetic mutations (e.g.,
CEBPA, FLT3, NPM1, PDGFR), it is believed that these two RUNX1
mutations may have exerted a stronger dominant negative effect
than either RUNX1 mutation alone, thus leading to malignancy
with myelomonocytic differentiation. These hypotheses bear exp-
erimental study.
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